The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Infinity Pharmaceuticals Inc

Nasdaq: INFI
Last

(U.S.) $15.98

Today's change+0.18 +1.14%
Updated January 27 1:51 PM EST. Delayed by at least 15 minutes.
 

Infinity Pharmaceuticals Inc

Nasdaq: INFI
Last

(U.S.) $15.98

Today's change+0.18 +1.14%
Updated January 27 1:51 PM EST. Delayed by at least 15 minutes.

Infinity Pharmaceuticals Inc up (U.S.)$0.18

Infinity Pharmaceuticals Inc is up today by (U.S.)$0.18 or 1.14% to (U.S.)$15.98. Over the last five days, shares have gained 8.63% and outperformed the S&P 500 index over the last 52 weeks with a 23.49% increase in price.

Key company metrics

  • Open(U.S.) $15.65
  • Previous close(U.S.) $15.80
  • High(U.S.) $16.12
  • Low(U.S.) $15.57
  • Bid / Ask(U.S.) $15.97 / (U.S.) $15.99
  • YTD % change-5.39%
  • Volume347,837
  • Average volume (10-day)626,582
  • Average volume (1-month)866,115
  • Average volume (3-month)764,871
  • 52-week range(U.S.) $8.40 to (U.S.) $18.25
  • Beta1.12
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.27
Updated January 27 1:51 PM EST. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue1610--0
Total other revenue--------
Total revenue161000
Gross profit--------
Total cost of revenue--------
Total operating expense53354133
Selling / general / administrative8776
Research & development45283427
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income108-35-41-33
Interest income (expense), net non-operating-5-3-1--
Gain (loss) on sale of assets--------
Other--------
Income before tax103-38-42-33
Income after tax103-38-42-33
Income tax, total--000
Net income103-38-42-33
Total adjustments to net income-2------
Net income before extra. items103-38-42-33
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items101-38-42-33
Inc. avail. to common incl. extra. items101-38-42-33
Diluted net income101-38-42-33
Dilution adjustment--000
Diluted weighted average shares50494848
Diluted EPS excluding extraordinary itemsvalue per share2.03-0.78-0.87-0.68
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share2.03-0.78-0.87-0.68